Skip to content
HomeLatest newsInnovationAward criteria
speaker

Award criteria

About the award:

The Scholars Award is a three-year award in the gross amount of $150,000, which will be paid to the University (the “Recipient”) for the benefit of the Johnson & Johnson Scholar and her research, with the understanding that the Recipient will administer the funds. The Scholars Award will be paid in three (3) installments of U.S. $50,000 per year of the three-year scholarship period, payable in 2022, subject to compliance with the terms and conditions of the program’s Agreement. Winners achievements will also be showcased at a symposium.

The following award criteria applies:

Standards for evaluation:

Judges will use the following criteria to evaluate the applications:

  • Scientific/technical expertise exhibited
  • Novelty/innovation of the research
  • Potential impact of the research
  • Feasibility of the research

You must be a woman working in the field(s) of Science, Technology, Engineering, Mathematics, Manufacturing and Design (STEM2D).

You must be an early to mid-career women working within a STEM2D university department at the time of application at an accredited academic university, institution or design school. Examples include a non-tenured assistant professor, assistant professor or associate professor.

The female scholar should have a minimum degree for the appropriate field:

  • Science; M.D., Ph.D.
  • Technology; Ph.D.
  • Engineering; Ph.D.
  • Math; M.S., Ph.D.
  • Manufacturing; Ph.D.
  • Design; M.A., M.S., MDes, MArch, MFA, MLA, Ph.D.

WiSTEM2D Scholars Award

The Johnson & Johnson WiSTEM²D Scholars Award Program will help develop female leaders and support innovation in STEM fields.

More from Johnson & Johnson

This scientist couldn’t save his father from lung cancer—but the targeted treatments Robert Zhao, Ph.D., has since developed have helped countless others

Learn more about Zhao, his partnership with Johnson & Johnson and antibody-drug conjugates—a new type of cancer therapy that targets and kills cancer cells without harming healthy cells.

After their husbands were diagnosed with multiple myeloma, these 3 care partners became health equity activists

Kimberly Alexander, Michelle Ware-Ivy and Marsha Calloway-Campbell learned firsthand that Black individuals develop multiple myeloma at higher rates. That’s why they joined Johnson & Johnson’s That’s My Word® health equity campaign, which builds awareness about the disparities surrounding this rare blood cancer.

How Johnson & Johnson is working to get medications to people around the world who need them most

In the just-released 2024 Access to Medicine Index, the company ranks among the top 5 improving access to medicines.